Can Sarepta Beat Pfizer To A Duchenne Gene Therapy Breakthrough?

New Updates Sway Sentiment Behind Sarepta

 
• By Andrew McConaghie
  
Sarepta Building 2
Sarepta's is already earning revenues from its three exon-skipping DMD drugs, but a gene therapy could represent a true breakthrough for patients and their families. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip